On November 5, 2024 Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology and autoimmune diseases, reported an upcoming poster presentation at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in San Diego from December 7-10, 2024 (Press release, Orna Therapeutics, NOV 5, 2024, View Source [SID1234647737]). The presentation will outline data supporting the exploration of its in vivo CAR therapy approach in oncology and autoimmune diseases. Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: In Vivo panCAR-Mediated Depletion of B cells in Non-Human Primates Using a Circular (oRNA) Anti-CD20 CAR

Speaker: Dr. Akinola Emmanuel, Principal Scientist, Drug Discovery, Orna Therapeutics

Date/Time: Sunday, December 8, 2024 6:00 PM – 8:00 PM PT

Publication Number: 3427

Session Name: 702. CAR-T Cell Therapies: Basic and Translational: Poster II